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2Centre Hospitalier Universitaire Vaudois, University of Lausanne, Rue Bugnon 46, CH-1010 Lausanne, SwitzerlandSummary ment viral kinetics [1,2]. Recently, four genome-wide associationRecent genome-wide association studies (GWAS) have identiﬁed
genetic variations near the IL28B gene which are strongly associ-
ated with spontaneous and treatment-induced clearance of hep-
atitis C virus (HCV) infection. Protective IL28B variations are
strongly associated with on-treatment viral kinetics and approx-
imately 2-fold increased sustained virologic response (SVR) rates
in HCV genotype 1 and 4 patients. In HCV genotype 1 patients,
IL28B variations were shown to be the strongest pre-treatment
predictor of virologic response. In the treatment of HCV genotype
2 and 3 infected patients, IL28B variations play only a minor role.
Preliminary data indicate that IL28B variations are also associated
with treatment outcome of regimens, including directly acting
antiviral (DAA) agents, though their impact seems to be attenu-
ated compared to standard treatment. Here, we review these
important ﬁndings and discuss possible implications for clinical
decision making in the treatment of HCV infection.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Standard treatment of chronic hepatitis C with pegylated inter-
feron-a (pegIFN-a) and ribavirin results in sustained virologic
response (SVR) rates of less than 50% in HCV genotype 1 or 4
infected patients, contrasted by SVR rates of 70–90% in HCV
genotype 2 and 3 patients [1]. Thus far, individual prediction of
treatment outcome and deﬁnition of treatment durations were
based on a variety of parameters on the patients and viral side,
such as the degree of liver ﬁbrosis, the HCV genotype, or on-treat-Journal of Hepatology 20
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(SNPs) near the IL28B gene (encoding IFN-k3) to be strongly asso-
ciated with spontaneous and treatment-induced clearance of
HCV infection [3–6]. In fact, HCV genotype 1 patients with
good-response IL28B SNPs achieve comparable SVR rates than
the ‘‘easy to treat’’ HCV genotype 2 and 3 patients in general
[3]. These ﬁndings aroused enormous attention of hepatologists
(and patients), and the implementation of such genetic informa-
tion in treatment algorithms will likely advance personalized
medicine in hepatitis C. Soon after publication of the pivotal
GWAS, numerous studies have conﬁrmed and extended our
knowledge on the importance of IL28B SNPs in the natural course
and treatment of HCV infection, and a commercially available test
of the IL28B rs12979860 genotype was developed. Though the
biological implications of IL28B variations are poorly understood,
results of these GWAS have also inspired many basic researchers
to focus their attention on the role of INF-k signaling in HCV
infection. These attempts may yield results of importance far
beyond viral hepatitis. Here, we review these important ﬁndings
and discuss potential clinical implications for the treatment of
hepatitis C.Genome-wide association studies (GWAS) and implications for
personalized medicine
According to various estimations, the sequence of the human
genome differs in approximately 0.1% from person to person
[7–9]. These inter-individual genetic variations may for example
inﬂuence regulatory sequences and thereby gene expression,
they may impact the splicing of gene products, alter the sequence
of non-coding RNAs, or they may directly result in changes of
protein-sequences and function [8]. Base-pair variations at a
given location with a minor allele frequency of >1% within a pop-
ulation are called single nucleotide polymorphisms (SNPs), in
contrast to so called rare variations which are present at lower
frequencies [7,8]. After the entire sequencing of the human gen-
ome, in particular the HapMap Project provided the basis for the
conduction of GWAS by drawing a detailed genome-wide map of
the organization of SNPs in haplotypes [10]. Haplotypes are a ser-
ies of variations/SNPs that tend to be inherited together, and their
knowledge allows the selection of marker SNPs throughout the
genome for GWAS. As a consequence, SNPs identiﬁed in GWAS
frequently are not causal variants, but are likely to correlate with11 vol. 55 j 692–701
Key Points  
Single nucleotide polymorphisms (SNPs) near the IL28B
gene (e.g. rs12979860 or rs809917) are strongly 
associated with spontaneous and treatment-induced 
clearance of hepatitis C Virus (HCV) infection. 
The biology of these genetic variations is poorly 
understood. Nevertheless, their chromosomal localization 
points to an important role of IFN-  signaling in HCV 
infection. 
Good-response IL28B SNPs are associated with 
approximately 2 fold increase SVR rates in HCV
genotype 1 and 4 patients. In HCV genotype 2 and 3 
patients, IL28B variations are only weakly associated 
with treatment response. 
IL28B variations impact treatment outcome of interferon-
-based therapy by being associated with very early on-
treatment viral kinetics, and IL28B variations are the 
strongest established pre-treatment predictor of 
treatment response in HCV genotype 1 patients. 
Both, donor and recipient IL28B genetic variations are 
associated with treatment outcome of recurrent hepatitis
C in liver transplanted patients.  
The effect of IL28B variations on outcome of treatment 
regimens including directly acting antiviral (DAA) agents 
is unclear at the moment, though preliminary data 
indicate an attenuated association. 
Collectively, IL28B SNPs may play an important role in 
the management of HCV infection, in particular in 
defining individualized treatment durations, in the 
selection of optimal treatment regimens, and potentially 
even in the allocation of appropriate liver grafts to HCV 
infected patients. 
JOURNAL OF HEPATOLOGYa causal variant within a haplotype [8,11,12]. In the last years,
numerous GWAS have been conducted (listed in http://www.ge-
nome.gov/26525384), and many SNPs were associated with com-
plex diseases such as diabetes mellitus, atherosclerosis, or
various types of cancer [8,11,12]. However, most identiﬁed SNPs
explained only little of the estimated genetic basis of a disease,
and whole-genome sequencing may uncover rare variations with
major impact at an individual level. In these regards, the strong
association of IL28B variations with spontaneous and treat-
ment-induced clearance in HCV infected patients is an exciting
exception. The random approach of GWAS also has a high poten-
tial to identify unexpected pathways involved in pathogenesis. In
addition, many disease-associated SNPs identiﬁed by GWAS are
not located within protein-coding regions of the genome (some
were even far away from any known coding region), which high-
light the regulatory importance of non-coding DNA regions
[9,13]. However, GWAS can assess only part of genetic (and no
epigenetic) variations between individuals, and important inter-
individual differences such as copy-number variations, alterna-
tive splicing variations, or deletions may be only uncovered byJournal of Hepatology 201next-generation technologies like whole-genome or RNA
sequencing [7,13–16].Biology of interferon-k (IFN-k)
The IL28B gene encodes for interferon-k3 (IFN-k3), which consti-
tutes the IFN-k family together with IFN-k1 (encoded by IL29)
and IFN-k2 (encoded by IL28A). The IL28A, IL28B, and IL29 genes
are located on chromosome 19 in close proximity [17]. Interfer-
ons (IFNs) are categorized into three different families, type 1
IFNs (mainly IFN-a, -b), type 2 IFNs (only IFN-c), and type 3
IFNs (IFN-k1–3) [18]. Due to their molecular structure, type 3
IFNs belong to the interleukin-10 (IL-10) superfamily, but func-
tionally they are closely related to type 1 IFNs which play a
major role in antiviral immunity [19]. Viral infection is sensed
in cells by pattern recognition receptors such as toll-like recep-
tors (TLR) or retinoic acid-inducible gene I (RIG-I)-like-helicases,
which lead to a signal cascade inducing the interferon response
factors 3 or 7 (IRF3, IRF7) [18]. Importantly, IFN-k2/3 and IFN-a
expression is induced by IRF7, and IFN-k1 and IFN-b expression
is induced by IRF3 and IRF7 [20,21]. via signaling through the
JAK-STAT pathway, both IFN-a/b and IFN-k1–3 induce a large
number of widely overlapping interferon-stimulated genes
(ISGs), which orchestrate an antiviral cellular state, Fig. 1
[22–24]. However, IFN-a/b and IFN-k1–3 engage completely
different transmembrane receptors, the IFN-a receptor (IFNAR)
complex, and the heterodimeric IL28-Ra/IL-10R2 receptor com-
plex, respectively [25]. Though type 1 and type 3 IFN-signalings
converge in the JAK-STAT pathway, their binding to different
receptors may result in different kinetics of ISG expression
[26]. Moreover, tissue distributions of the IFNAR and the IL28-
Ra/IL-10R2 receptor complexes differ signiﬁcantly [20]. In
humans, IL28-Ra/IL-10R2 expression is restricted to hepato-
cytes, epithelial cells, and plasmacytoid dendritic cells, whereas
IFNAR is broadly expressed in numerous tissues. The cellular
sources of IFN-k are predominantly plasmacytoid dendritic cells,
probably macrophages (including Kupffer cells), and potentially
other cell types like liver sinusoidal endothelial cells. In con-
trast to humans, mouse hepatocytes do not respond to IFN-k
signaling [20].
It is important to keep in mind that nearly all IL28B variations
associated with spontaneous and treatment-induced clearance
are not located within coding regions, but only in close proximity
of the IL28B gene. By ﬁne mapping strategies only, a non-synon-
ymous coding variation (rs8103142) in exon 2 of IL28B was iden-
tiﬁed, but thus far no functional differences between the
resulting IFN-k3 variants (Lys70Arg) could be shown [27]. More-
over, data on expression levels of INF-k3 in patients with differ-
ent IL28B genotypes remain conﬂicting, and only some studies
found higher INF-k3 mRNA or protein levels in the liver or blood
of patients with good-response IL28B alleles [5,27–30]. Thus, the
highly suggestive link between IL28B variations and IFN-k3
signaling remains to be proven.IL28B SNPs and spontaneous clearance of HCV infection
Spontaneous clearance of HCV occurs in only 15–50% of all HCV
infected individuals, while the majority of patients develop a
chronic infection. Thomas et al. found that IL28B rs12979860 is1 vol. 55 j 692–701 693
Fig. 1. IFN-a/b and IFN-k signaling pathways. IFN-a/b and IFN-k are both induced by IRF7/IRF3, and they are signaling through the JAK/STAT pathway to induce a large
number of widely overlapping interferon-stimulated genes (ISGs). However, IFN-a/b and IFN-k engage completely different receptors, which also differ signiﬁcantly in their
tissue distribution. Plasmacytoid dendritic cells are a main cellular source of IFN-k, whereas IFN-a/b is broadly expressed. Please note that IFN-a/b and IFN-k can also act in
a paracrine manner, not just in the autocrine way illustrated in this Figure. IL28B genetic variations may alter for example expression, stability, or receptor binding of IFN-
k3. IFN, interferon; MAVS, mitochondrial anti-viral signaling protein; RIG-I, retinoic acid-inducible gene I; TRIF, Toll-IL-1 receptor domain-containing adaptor inducing IFN-
b; IRF, interferon-response factor; TLR, toll-like receptor; IFNAR, IFN-a receptor complex; Jak, janus kinase; TYK, tyrosine kinase; STAT, signal transducers and activators of
transcription; ISG, interferon-stimulated genes.
Reviewstrongly associated with the chance to clear HCV spontaneously
in populations of African or European ancestry, with an approxi-
mately three times higher clearance rate in individuals with the
rs12979860 genotype C/C versus C/T, T/T [31]. The same IL28B
alleles were associated in the very ﬁrst GWAS on treatment
response with SVR versus non-SVR, respectively [3]. In the Swiss
hepatitis C cohort, the association between IL28B variations (top
hit rs809917) and spontaneous clearance reached genome-wide
signiﬁcance [4]. In the homogeneous German anti-D cohort, com-694 Journal of Hepatology 201prising exclusively women infected with HCV genotype 1b,
rs12979860 C/C versus C/T, T/T was not only associated with
spontaneous clearance, but also with jaundice, providing a link
to the clinical observation that patients with symptomatic acute
hepatitis C are more likely to clear the virus than those with
silent disease [32]. Intriguingly, the study by Thomas et al. also
characterized the frequencies of rs12979860 C versus T alleles
in several world-wide populations [31]. The highest frequencies
of the protective C allele were observed in East Asia, frequencies1 vol. 55 j 692–701
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were intermediate in Europe, and lowest in Africa. This
geographic distribution of C/T allele frequencies largely parallel
reported rates of spontaneous and treatment induced clearance
in these areas.
Interestingly, several [4,33–36] but not all [37] studies
reported lower IL28B rs12979860 C versus T allele frequencies
in patients infected with HCV genotypes 1 versus 2 or 3. For
example, in a large German cohort the rs12979860 C/C genotype
was found in 42.7% of HCV genotype 2 and 3 patients, in 33.9% of
HCV genotype 1 patients, and in 49% of uninfected control indi-
viduals [35]. The frequency of the protective C allele in HCV geno-
type 2/3 patients, which is close to that of uninfected individuals,
allows speculating that protective IL28B variations provide a
more substantial advantage in acute HCV genotype 1 versus 2/3
infection, or that spontaneous clearance rates are higher in HCV
genotype 1 infection. Appropriate studies are required to address
this issue.Table 1. Characteristics of four pivotal GWAS on treatment-induced HCV clearance.
n 
Ancestry 
HCV genotypes 
Treatment regimen 
Outcome 
Top 5 SNPs 
associated with 
treatment response#
SVR (%) 
Ge et al., [3] 
North America  
1137 
Caucasian, African-
American, Hispanic 
1 
pegIFN-α-2a/ -2b + 
weight based ribavirin
within randomized  
controlled clinical trials***
SVR vs. non-response
rs12979860 
(p = 1.21x10-28) 
rs12980275 
(p = 2.82x10-27) 
rs8099917 
(p = 4.37x10-26) 
rs12972991 
(p = 1.88x10-21) 
rs8109886 
(p = 1.32x10-16) 
Caucasian:  
82 vs. 40  
African-American: 
53 vs. 18 
(rs12979860 C/C vs.
C/T,T/T) 
Tanaka et al. [,
napaJ
142* 
Japanese 
1 
pegIFN- 2-/a2-
weight based 
ribavirin***
SVR/relapse vs
response, SVR
non-response  
rs8099917 
(p = 3.11x10-15)
rs7248668 
(p = 8.52x10-14)
rs11881222 
(p = 2.31x10-14)
rs8105790 
(p = 1.5x10-14) 
rs12980275 
(p = 1.93x10-13)
Not applicable 
case-control de
⁄These studies included replication cohorts. In the present Table, only numbers and res
⁄⁄Additional patients were assessed for spontaneous HCV clearance.
⁄⁄⁄Patients were excluded who received <80% of recommended dose for pegIFN-a/ribav
et al., Rauch et al.).
#Different platforms were used for GWAS. Therefore, not all SNPs were equally represen
##SNPs were also associated with spontaneous clearance in this study.
Journal of Hepatology 201Implications for the treatment of acute hepatitis C
Early treatment of acute hepatitis C with 24 weeks of mono-
therapy with (pegylated) IFN-a results in HCV eradication in
the majority of patients. However, the optimal time-point for
treatment initiation is still under debate, since late treatment ini-
tiation may reduce the chance of HCV clearance, whereas very
early treatment initiation will lead to treatment of a number of
patients who would have cleared HCV spontaneously [38]. Due
to signiﬁcant side-effects and costs of IFN-a based therapy,
IL28B genetic testing may help to identify those individuals with
low chance of spontaneous clearance for early treatment initia-
tion. Whether IL28B SNPs also impact treatment response in
acute hepatitis C has not been comprehensively investigated.
However, a study in approximately 50 patients with recent HCV
infection (up to 24 months after sero-conversion) found no effect
of IL28B variations on the outcome of IFN-a based therapy [39]. In]6
+b
. non-
 vs.
 
 
 
 
due to 
sign 
Suppiah et al., [5] 
Australia, Europe  
293* 
Caucasian 
1 
pegIFN-α + weight-
based ribavirin 
SVR vs. non-response 
rs8099917 
(p = 7.06x10-8) 
56 vs. 36
T/T vs. T/G, G/G) 
Rauch et al., [4] 
Switzerland  
465**
Caucasian 
1, 2, 3, 4 
pegIFN-α-2a/ -2b + 
weight based 
ribavirin***
SVR vs. non-response 
rs8099917 
(p = 5.47x10-8) 
rs8105790 
(p = 8.07x10-8) ##
74 vs. 50
T/T vs. T/G, G/G) 
(rs8099917 (rs8099917 
ults for the initial GWAS are shown.
irin throughout treatment period (Ge et al.) or during the ﬁrst 12 weeks (Tanaka
ted in each GWAS. Only SNPs that reached genome-wide signiﬁcance are shown.
1 vol. 55 j 692–701 695
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addition, no signiﬁcant impact of IL28B variations on the outcome
of treatment of acute hepatitis C in human immunodeﬁciency
virus (HIV) coinfected patients was observed [40].IL28B SNPs and treatment-induced clearance of chronic HCV
genotype 1 infection
In 2009 and 2010, four independent GWAS on response to treat-
ment of chronic hepatitis C with pegIFN-a and ribavirin were
published [3–6]. In each of these GWAS, only SNPs around the
IL28B gene reached genome-wide signiﬁcance for the association
with treatment outcome. All identiﬁed IL28B SNPs correlate with
each other and can, therefore, be clustered in haplotypes. Consis-
tently, rs12979860 C (good-response allele) versus T (poor-
response allele) and rs809917 T (good-response allele) versus G
(poor-response allele) showed the strongest association with
SVR of thus far characterized SNPs. Both SNPs are in strong link-
age disequilibrium, but allele frequencies in particular of
rs809917 differ somewhat between world-wide populations.
Therefore, the predictive power of both SNPs may vary between
different cohorts, as for example rs809917 was only a weak pre-
dictor of SVR in African–American patients [3].
In the largest GWAS including more than 1000 HCV genotype
1 patients, rs12979860 C/C versus T/T was associated with a more
than 2-fold higher chance to achieve a SVR [3]. SVR rates accord-
ing to the heterozygous genotype rs12979860 C/T were only
slightly better compared to rs12979860 T/T. Importantly, these
ﬁndings were comparable in patients of European–American,
African–American, and Hispanic ancestry, though SVR rates in
African–American patients generally were lower compared to
European–Americans. However, the IL28B genetic background
was a stronger predictor of SVR than ancestry, and different
SVR rates between these ethnic groups were explained to approx-
imately 50% by lower rs12979860 C/C frequencies in African–
Americans. In the three other GWAS, comparable associations
between IL28B variations and treatment-response were observed
in populations of Asian, European, and European–Australian
ancestry, (Table 1) [4–6].
Several studies revealed comparable associations between
IL28B variations and treatment-induced HCV clearance in
patients co-infected with HIV [4,40–42]. For example, one study
in HIV co-infected patients reported 2–3-fold higher SVR rates
for HCV genotypes 1 and 4 according to rs12979860 C/C versus
C/T, T/T, but no difference for HCV genotype 3 according to
rs12979860 C/C versus C/T, T/T [42].IL28B SNPs and established predictors of virologic response
Thompson et al. performed an intention-to-treat analysis of 1671
patients of the IDEAL study and of additional 67 patients of
another clinical trial (adherent patients of this cohort were
reported in the GWAS by Ge et al.) [43]. In these HCV genotype
1 patients, IL28B rs12979860 was the strongest pre-treatment
predictor of virologic response and explained approximately
15% of inter-individual variability of SVR. In contrast, other signif-
icant pre-treatment predictors of treatment outcome (hepatic
ﬁbrosis stage, baseline viral load, fasting glucose level, body mass
index (BMI), ethnic background) each accounted for not more
than 5% of variability of SVR.696 Journal of Hepatology 201In this study, Thompson et al. also demonstrated that the
rs12979860 genotype is strongly associated with on-treatment
viral kinetics. At treatment week 2, Caucasian patients with the
rs12979860 C/C, C/T, and T/T genotype had experienced a median
2.6, 0.9, and 0.6 log10 HCV RNA decline, respectively. In African–
American patients, similar tendencies were observed, but viral
load reductions were slightly lower in all rs12979860 groups.
Despite ongoing decreases, differences in HCV RNA serum con-
centration were of similar magnitude at treatment week 4 and
12, compared to treatment week 2. Thus, IL28B variations are
associated with (very) early on-treatment viral kinetics, which
lead to increased rapid virologic response (RVR) and early viro-
logic response (EVR) rates. When comparing the predictive value
of rs12979860 and RVR, Thompson et al. found that the
rs12979860 genotype had a higher sensitivity and a higher neg-
ative predictive value of SVR, but RVR had the highest positive
predictive value and a better speciﬁcity of SVR. In addition,
patients with RVR achieved high SVR rates independently of the
rs12979860 background. In contrast, the rs12979860 genotype
was strongly associated with SVR in patients who did not achieve
a RVR. However, it is important to keep in mind that RVR is rare
in HCV genotype 1 patients, and RVR itself is associated with
rs12979860 C/C.
The ﬁndings by Thompson et al. were extended by another
study that analyzed the inﬂuence of IL28B variations on viral
kinetics during the very ﬁrst days of treatment with pegIFN-a
and ribavirin [44]. In this study, IL28B variations were strongly
associated with differences in the 1st phase HCV RNA decline
between day 1 and 4 of therapy. IL28B variations were also asso-
ciated with the 2nd phase decline of HCV RNA from the second
throughout the fourth week of therapy, but this association was
no longer signiﬁcant after adjustment for the 1st phase decline.
Thus, associations of IL28B variations with RVR and SVR appear
to be related to a strong impact on very early viral kinetics during
treatment, which reﬂects the antiviral effectiveness of IFN-a.
Whether IL28B variations are also associated with residual differ-
ences in the 2nd phase HCV RNA decline is unclear at the
moment.IL28B SNPs in patients infected with HCV genotypes 2, 3, and 4
HCV genotype 1 patients with a good-response IL28B genetic
background still achieve somewhat lower SVR rates than HCV
genotype 2 and 3 patients in general. Thus, it is obvious that
the HCV genotype will remain an important independent pre-
treatment predictor of virologic response. Directly acting
antiviral (DAA) agents will improve treatment options for HCV
genotype 1 patients in the very near future, whereas the develop-
ment of agents effective against other HCV genotypes is at an
earlier stage [45]. Thus, the impact of IL28B variations on the out-
come of standard therapy in HCV non-genotype 1 infected
patients requires attention.
Several studies clearly showed that associations between
IL28B variations and RVR and SVR are comparable between HCV
genotype 1 and 4 patients [4,42,46]. In contrast, results from
studies in HCV genotype 2 and 3 patients remain conﬂicting.
Mangia et al. analyzed the role of IL28B rs12979860 in treatment
response in a large cohort of HCV genotype 2 and 3 patients who
were treated with pegIFN-a and ribavirin either for 24 weeks
(standard treatment), or for 12 or 24 weeks, according to whether1 vol. 55 j 692–701
JOURNAL OF HEPATOLOGY
they achieved an RVR [37]. Rs12979860 was neither associated
with RVR and SVR in the standard treatment arm, nor with SVR
in patients who achieved a RVR and who were treated for
12 weeks only. However, in patients who did not achieve an
RVR and who received 24 weeks of treatment, rs12979860 was
signiﬁcantly associated with SVR (SVR rates 87%, 67%, and 29%
for rs12979860 C/C, C/T, and T/T, respectively). In contrast to
Mangia et al., Sarrazin et al. found an association of rs12979860
with RVR in HCV genotype 2 and 3 patients, and also with SVR
in those patients who did achieve a RVR [35]. In the latter study,
the proportion and absolute number of HCV genotype 3 versus 2
patients was much higher compared to the Mangia study, but
treatment regimens were more heterogeneous. Several other
studies yielded mixed results, though most studies failed to show
a signiﬁcant association of IL28B variations with SVR [4,33,40,
47–49].IL28B SNPs and treatment with directly acting antiviral agents
With the expected approval of the HCV NS3-4A protease inhibi-
tors telaprevir and boceprevir in 2011, numerous patients with
HCV genotype 1 infection will likely be subjected to triple ther-
apy regimens, including telaprevir or boceprevir in combination
with pegIFN-alfa and ribavirin [50–57]. Other directly acting anti-
viral (DAA) agents in advanced clinical development include HCV
NS5B polymerase inhibitors, HCV NS5A inhibitors, or the cyclo-
philin A inhibitor Debio-025 (alisporivir) [45,58]. Preliminary
data on the role of IL28B variations in predicting response to tri-
ple-therapy regimens are available. A Japanese study analyzed 72
HCV genotype 1 patients who were either treated for 12 weeks
with telaprevir plus pegIFN-a and ribavirin (n = 20), or for
12 weeks with telaprevir plus pegIFN-a and ribavirin followedHCV  
genotype 
coverage
larivitnA
ytivitca
Barrier to 
resistance 
rotibihniA4-3SN + +++ --
rotibihniA5SN +++ +++ -  
Non-nucleoside
NS5B inhibitor - ++ --
Nucleosid 
NS5B inhibitor +++ ++ +
Cyclophilin 
inhibitor +++ ++ ++
Fig. 2. Features of emerging directly acting antiviral (DAA) agents for the
treatment of chronic hepatitis C. DAA agents differ signiﬁcantly with respect to
HCV genotype coverage, antiviral activity, and barrier to resistance. The risk of
resistance development increases with time of active HCV replication during
exposure to DAA agents, and may therefore be higher in patients with poor-
response IL28B genotype. Intensive research is required to deﬁne the precise
value of IL28B variations in predicting treatment response to regiments including
DAA agents.
Journal of Hepatology 201by additional 12 weeks of pegIFN-a and ribavirin only (n = 52)
[59]. Overall SVR rates after 12 and 24 weeks of total therapy
were 45% and 67%, respectively. In this study, both rs809917 T/
T versus G/T, G/G and rs12979860 C/C versus C/T, T/T were asso-
ciated with a more than 2-fold higher chance to achieve SVR after
triple therapy. In contrast, on-treatment viral kinetics during
treatment with the HCV protease inhibitor TMC435 in combina-
tion with pegIFN-a and ribavirin were only slightly inﬂuenced by
IL28B variations [60].
Theoretically, the ﬁnding that IL28B genetic variations are
strongly associated with differences in early on-treatment viral
kinetics during standard treatment suggests a higher risk of resis-
tance development to DAA agents in patients with poor-response
IL28B alleles. Since DAA agents differ signiﬁcantly in their barrier
to resistance development, the impact of IL28B SNPs on treat-
ment–response may vary among DAA agents (Fig. 2) [58]. Indeed,
a small clinical trial found no signiﬁcant association of IL28B SNPs
with RVR rates during treatment with the nucleotide–analog HCV
polymerase inhibitor PSI-7977 in combination with pegIFN-a and
ribavirin [61]. In contrast, the rs12979860 genotype was signiﬁ-
cantly associated with on-treatment virologic response rates
during combination therapy with the non-nucleotide HCV
polymerase inhibitor ANA598 plus pegIFN-a and ribavirin (RVR
rates 80% versus 31% for C/C versus C/T, T/T, respectively) [62].
Overall, IL28B variations seem to play an attenuated role during
triple therapy, but additional research is required before ﬁnal
conclusions can be drawn.Implications for the treatment of chronic hepatitis C
IL28B SNPs provide a strong predictive value for the outcome of
standard therapy in the difﬁcult to treat HCV genotype 1 and 4
patients. Due to the availability of this information before treat-
ment initiation, IL28B SNPs will likely enrich future decision-
making in the management of chronic hepatitis C. Before IL28B
genotypes can be deﬁnitely included in treatment recommenda-
tions, analyses of appropriate randomized controlled clinical tri-
als are mandatory, in which treatment arms are compared after
stratiﬁcation of patients according to IL28B genotype. IL28B SNPs
were shown to be the strongest pretreatment-predictor of treat-
ment outcome in HCV genotype 1 patients. Nevertheless, it was
estimated that IL28B variations account for ‘‘only’’ about 15% of
inter-individual variability of SVR, a ﬁnding which supports the
importance of additional predictors of treatment response, possi-
bly including more recently established predictors such as vita-
min D deﬁciency, interferon-c-inducible protein-10 (IP-10)
serum levels, or steatosis/insulin resistance [1,2,43,63–67]. In this
context, models for the prediction of SVR which include a variety
of parameters in combination with IL28B genotype might be of
value, since they were shown to achieve higher accuracy in pre-
dicting treatment response compared to the IL28B genotype alone
[63,68–70]. In addition, the role of other genetic factors that
inﬂuence spontaneous or treatment-induced HCV clearance, such
as genes encoding the natural killer (NK) cell receptor KIR2DL3
and its ligand, human leukocyte antigen C group 1 (HLA-C1),
should be re-analyzed in relationship to IL28B genotype [71–
73]. Thus, clinical decisions surely should not be based exclu-
sively on IL28B genotyping, and a poor-response IL28B genetic
background alone should never be an argument to withhold ther-
apy from a patient [74].1 vol. 55 j 692–701 697
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At present, it is one of the most relevant questions in the man-
agement of chronic HCV genotype 1 infection whether early stan-
dard therapy is advisable in a given patient, or whether treatment
should be postponed in anticipation of the approval of DAA
agents. Diagnosing a good-response IL28B genotype may substan-
tially back up immediate initiation of standard therapy in a
patient (Fig. 3). In contrast, postponement of therapy appears to
be a reasonable strategy in patients with a poor-response IL28B
genetic background and mild to moderate liver ﬁbrosis. This
strategy may be further supported by preliminary data showing
that poor-response IL28B genotypes might be associated with
decelerated liver ﬁbrosis progression (see below). Triple therapy
with pegIFN-a and ribavirin in combination with DAA agents in
general is substantially more effective in HCV genotype 1 patients
compared to standard therapy [50–57]. However, triple therapy
is also burdened with additional signiﬁcant side effects and cost.
Thus, IL28B SNPs may still be used after approval of DAA agents to
select patients in whom standard therapy might still be justiﬁed.
Most patients with good-response IL28B genotypes will have a
high chance of cure with both regimens, and factors such as pref-
erence of short treatment duration, risk of anemia, or presence of
skin disorders may be crucial for individual decisions.
IL28B variations may also signiﬁcantly support individualizing
treatment durations (Fig. 3). In this context, it is important that
IL28B variations provide additional, discrete information to on-
treatment viral kinetics. Though RVR has a higher speciﬁcity
and positive predictive value for SVR than a good-response
IL28B genotype, IL28B SNPs exhibit a better negative-predictive
value and sensitivity for SVR [43]. In addition, IL28B SNPs are
strongly associated with SVR in patients who do not achieve
RVR [43]. Sarrazin et al. retrospectively evaluated the importance
of IL28B SNPs in completely individualized treatment durationsrs12979860 CC  rs12979860 CT/TT 
pegIFN + riba 
24-48 weeks  
pegIFN + riba + TVR/BOC 
(12?)-24 weeks if eRVR 
48 weeks if no eRVR
•
• • pegIFN + riba + TVR/BOC  
24 weeks if eRVR 
48 weeks if no eRVR 
• pegIFN + riba (48-72 weeks) 
if contraindication to  
triple therapy 
•
quadrupel therapy? •
pegIFN + riba + 
NS5B/cyclophilin inhibitor?
HCV genotype 1 infection
Fig. 3. Possible treatment algorithms for chronic HCV genotype 1 infected
patients according to IL28B alleles. Instead of rs12979860 C/C versus C/T, T/T,
other IL28B SNPs may be used. The suggested treatment algorithms are of
hypothetical nature, and randomized controlled clinical studies are required, in
which patients are stratiﬁed according to IL28B genotypes. Moreover, IL28B SNPs
should not be used as exclusive predictors of treatment response, and treatment
algorithms may be modiﬁed according to other predictors of virologic response.
TVR, telaprevir; BOC, boceprevir; eRVR, extended rapid virologic response (HCV
RNA below limit of detection at weeks 4 and 12 during treatment).
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patients [75]. Duration of treatment was deﬁned by a response-
guided approach according to the ﬁrst time when HCV RNA fell
below the limit of detection. Importantly, SVR rates were consis-
tently higher in patients with IL28B rs12979860 genotype C/C
(85% SVR), compared to C/T (58% SVR) and T/T (46% SVR). Thus,
patients with good-response IL28B genotypes may be optimal
candidates for individualized durations of standard treatment
with pegIFN-a and ribavirin. At present, the role of IL28B varia-
tions in response-guided approaches during triple-therapy regi-
mens is unclear, though one might speculate that 12–24 weeks
of triple therapy may be sufﬁcient to achieve high SVR rates in
patients with good-response IL28B genotypes.
Apparently, HCV genotype 1 (and 4) patients with poor-
response IL28B alleles should be considered as difﬁcult to cure
patients. Traditional approaches such as prolonged therapy with
pegIFN-a and ribavirin are of limited efﬁcacy [76]. In contrast,
phase II and III clinical trials have evidenced an enormous poten-
tial of telaprevir or boceprevir in combination with pegIFN-a and
ribavirin in previous partial non-responders and relapsers to
standard therapy [50,55]. These cohorts are presumably enriched
with patients carrying poor-response IL28B alleles. It is, therefore,
likely that patients with poor-response IL28B alleles will strongly
beneﬁt from triple therapy regimens. Though preliminary data
indicate an attenuated association of IL28B variations with
response to triple therapy as well, longer treatment durations
(48 weeks) may be required in patients with poor-response
IL28B alleles. Unfortunately, treatment of prior null-responders
to standard therapy, which in most cases will carry poor-
response IL28B alleles, will be still unsatisfactory with telapre-
vir-based triple therapy (boceprevir was not evaluated in
null-responders) [55]. Therefore, alternative treatment strategies
such as quadruple therapy or treatment with DAA agents with a
higher genetic barrier to resistance may be optimal in subgroups
of patients with poor-response IL28B alleles, and in particular in
prior null-responders to standard therapy (Fig. 3).
In HCV genotype 2 and 3 patients, IL28B variations in general
are only weakly associated with SVR. However, a poor-response
IL28B genotype might indicate a need for prolonged therapy of
48 weeks in HCV genotype 2 and 3 patients who do not attain
an RVR [37]. Whether a good-response IL28B genotype in HCV
genotype 2 and 3 patients may be an argument of shortened
treatment duration (e.g. 12 weeks) is unclear at the moment.IL28B SNPs in liver transplanted patients with recurrent
hepatitis C
Recurrent hepatitis C after liver transplantation is almost univer-
sal and has a substantial impact on graft and overall survival [77].
Thus, prevention or treatment of HCV liver graft reinfection is of
major importance. Unfortunately, pegIFN-a and ribavirin are of
limited efﬁcacy and poorly tolerated in liver transplanted
patients. Employing IL28B SNPs in the management of post-trans-
plant recurrent hepatitis C would be complicated by the genetic
chimerism of transplanted patients, in whom liver donor and
recipient IL28B genotypes may differ. Intriguingly, several retro-
spective studies have shown that both liver donor and recipient
IL28B variations are associated with response to (peg)IFN-a based
therapy of recurrent hepatitis C [28,78,79]. In the largest study,
both donor and recipient IL28B variations were strong and inde-1 vol. 55 j 692–701
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pendent predictors of SVR, with minimal SVR rates in patients
with donor and recipient poor-response IL28B genotype, interme-
diate SVR rates in patients with a good-response IL28B genotype
of either the donor or the recipient, and excellent SVR rates in
patients with good-response IL28B genotype of both the donor
and recipient [78]. In contrast to non-transplanted patients,
IL28B variations also appear to be important predictors of treat-
ment outcome in HCV genotype 2 and 3 infected patients with
recurrent hepatitis C [79].
In addition, IL28B variations were associated with parameters
reﬂecting the natural course of recurrent hepatitis C. For example,
recipient but not donor rs12979860 C/C versus C/T, T/T genotypes
were associated with delayed time to histologic recurrence of
hepatitis C and with decelerated ﬁbrosis progression of the liver
graft [78]. Thus, adequate prospective studies may also document
an effect of IL28B variations on survival rates of liver transplanted
patients with recurrent hepatitis C. This could theoretically jus-
tify an implementation of IL28B genetic testing in the allocation
of liver graft to HCV infected patients. Concrete treatment recom-
mendations on the basis of IL28B genotypes in liver transplanted
patients cannot be given at the moment. Nevertheless, IL28B
genetic testing appears to offer important opportunities in the
management of recurrent hepatitis C. For example, alternative
treatment strategies such as high-dose silibinin infusions after
liver transplantation might be considered in particular for
patients with a poor-response IL28B genetic background [80].IL28B SNPs and the natural course of hepatitis C
In addition to their striking role in spontaneous and treatment-
induced clearance, IL28B genetic variations seem to inﬂuence var-
ious phenotypes in chronic hepatitis C. Already the ﬁrst GWAS by
Ge et al. found that the same IL28B genotypes which are associ-
ated with treatment-induced clearance also correlate with higher
baseline viral loads [3]. This ﬁnding was conﬁrmed by various
studies including HCV genotype 1, 2, 3, and 4 patients
[4,33,35,46]. However, Thompson et al. reported that
rs12979860 genotype frequencies were similar when patients
were stratiﬁed in groups with low or high pretreatment HCV
RNA serum concentrations (threshold 600,000 IU/ml) [43]. This
may explain why both IL28B variations and baseline viral load
are independent and reliable predictors of treatment outcome.
Good-response IL28B variations are also associated with the
activity of chronic hepatitis C in terms of more severe necro-
inﬂammation in liver biopsies, as well as with higher alanine
and aspartate aminotransferase serum levels [35,81]. These ﬁnd-
ings may reﬂect a more pronounced immune response against
HCV in patients with good-response IL28B variations, which
may be true in particular for the adaptive immunity since
good-response IL28B variations are associated with lower levels
of interferon-stimulated genes (see below). Potential associations
of IL28B variations with hepatic ﬁbrosis are less well character-
ized. In a large GWAS, no association of IL28B variations with
the degree of liver ﬁbrosis at baseline was observed [82]. How-
ever, in the Swiss hepatitis C cohort study, which includes more
than 600 untreated patients with paired liver biopsies, ‘‘good-
response’’ IL28B variations were associated with more acceler-
ated progression of liver ﬁbrosis (Pierre-Yves Bochud, personal
communication).
Finally, metabolic abnormalities associated with chronic hep-
atitis C were correlated with IL28B genotypes. A profound associ-Journal of Hepatology 201ation of the good-response rs12979860 C/C genotype with higher
low-density lipoprotein (LDL) levels and other serum lipid
parameters was observed in HCV infected patients [83]. In addi-
tion, good response IL28B SNPs were associated with a lower inci-
dence of hepatic steatosis in patients with chronic hepatitis C
[84]. Interferons were shown to decrease serum levels of choles-
terol and other parameters of lipid metabolism [65]. The associ-
ation of good-response IL28B variations with higher LDL and
cholesterol serum levels may, therefore, reﬂect a lower pre-treat-
ment IFN-(k) activity in these patients.
In line, the expression level of interferon-stimulated genes
(ISGs) may provide a possible causal link between IL28B varia-
tions and such histologic and metabolic features of chronic hep-
atitis C. Two studies found a strong association of IL28B variations
with the expression level of ISGs in micro-arrays of liver speci-
mens [27,29]. However, a more recent study provided evidence
that this association may be not causal, but rather explained by
a frequent co-incidence of good-response IL28B alleles with low
ISG expression levels in those patients who will respond to IFN-
a-based therapy [85].Conclusions
IL28B genetic variations are the strongest established pre-treat-
ment predictor of SVR to standard therapy in HCV genotype 1
patients. Preliminary data indicate that IL28B variations also
exhibit an attenuated effect on response to triple therapy includ-
ing DAA agents. Though IL28B genetic variations are strongly
associated with on-treatment viral kinetics, they provide discrete
information to RVR and EVR. In view of these facts, IL28B SNPs
will likely play an important role in future management of
chronic hepatitis C, especially in the selection of appropriate
treatment regimens and in the deﬁnition of individualized treat-
ment durations. However, detailed analyses of randomized con-
trolled clinical trials in which patients were stratiﬁed according
to the IL28B genotype are necessary before IL28B genotyping
can be included in treatment recommendations. Clearly, clinical
decisions should not be made exclusively on the IL28B genotype,
and additional predictors of treatment response will maintain
importance. The strong effect of genetic variations near the
IL28B gene on spontaneous and treatment-induced clearance of
HCV also points to an important role of IFN-k-signaling in HCV
infection. This unexpected observation boosted basic research
on the role of IFN-ks in the pathogenesis of hepatitis C, as well
as the development of pegylated interferon-k1 (pegIFN-k1),
which is currently in phase II clinical evaluation for the treatment
of chronic hepatitis C.Conﬂict of interest
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